Our present in vitro and in vivo data are highly consistent with the findings reported in three other studies examining larger cohorts of prostate cancer patients and showing that patients with high endogenous WNT5A protein levels in their tumors have better outcomes and longer overall survival times compared with patients with low WNT5A levels [25,26,28]. Here, WNT5A is linked to prostate carcinoma.